Production of IL-1β, IL-1 receptor antagonist and IL-10 by mononuclear cells from patients with SLE

被引:26
作者
Andersen, LS [1 ]
Petersen, J [1 ]
Svenson, M [1 ]
Bendtzen, K [1 ]
机构
[1] Rigshosp Natl Univ Hosp, Inst Inflammat Res 7521, DK-2200 Copenhagen N, Denmark
关键词
IL-1; beta; IL-1ra; IL-10; mononuclear cells; SLE; IgG; lipopolysaccharide;
D O I
10.3109/08916939908993804
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Depositions of immune-complexes are responsible for many of the pathological features of systemic lupus erythematosus (SLE). For example, immune-complex-induced tissue damage in glomerulonephritis has been shown to be mediated, at least in part, by interleukin (IL)-1, Inappropriate production or function of IL-1 may therefore contribute to disease manifestations in SLE. We investigated lipopolysaccharide (LPS)- and adherent IgG-stimulated release of IL-1 beta, IL-1 receptor antagonist (IL-1ra) and IL-10, a potent modulator of IL-1, by blood mononuclear cells from patients,vith SLE, Mediator production was measured as ng cytokines/10(6) monocytes and compared with clinical parameters, Release of IL-1 beta was only detectable in LPS-stimulated cultures and substantially reduced in patients with both active and inactive disease (P < 0.001). LPS-stimulated IL-1ra release was normal and the IL-1ra/IL-1 beta ratio was therefore increased (P < 0.05) and correlated inversely to prednisolone dosage (P = 0.009). IgG-stimulated release of IL-1ra was reduced in patients,vith active disease compared to those with inactive disease and controls (P = 0.002). IL-10 release was similar in patients and controls. We conclude that monocytes from patients with active SLE are deficient in Fc gamma-R-mediated production of IL-1ra, whereas LPS-stimulated IL-1 beta release by SLE monocytes is reduced regardless of disease activity. The former may contribute to immune-complex-mediated tissue damage in SLE.
引用
收藏
页码:235 / 242
页数:8
相关论文
共 33 条
[1]   LONGITUDINAL-STUDY ON THE PRODUCTION OF AND CELLULAR-RESPONSE TO INTERLEUKIN A IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
ALCOCERVARELA, J ;
ALARCONSEGOVIA, D .
RHEUMATOLOGY INTERNATIONAL, 1995, 15 (02) :57-63
[2]   IgG for intravenous use, autologous serum and plasma induce comparable interleukin-1 receptor antagonist liberation from human mononuclear cells: An in vitro phenomenon depending upon plastic adherence [J].
Andersen, LS ;
Petersen, J ;
Svenson, M ;
Bendtzen, K .
AUTOIMMUNITY, 1995, 22 (02) :127-133
[3]  
AREND WP, 1985, J IMMUNOL, V134, P3868
[4]   INTERLEUKIN-1 RECEPTOR ANTAGONIST [J].
AREND, WP .
ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 :167-227
[5]   CYTOKINES AND NATURAL REGULATORS OF CYTOKINES [J].
BENDTZEN, K .
IMMUNOLOGY LETTERS, 1994, 43 (1-2) :111-123
[6]   INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISM AS A DISEASE SEVERITY FACTOR IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
BLAKEMORE, AIF ;
TARLOW, JK ;
CORK, MJ ;
GORDON, C ;
EMERY, P ;
DUFF, GW .
ARTHRITIS AND RHEUMATISM, 1994, 37 (09) :1380-1385
[7]  
Cochrane C G, 1973, Adv Immunol, V16, P185, DOI 10.1016/S0065-2776(08)60298-9
[8]  
FIELDS TR, 1983, J RHEUMATOL, V10, P550
[9]   CIRCULATING DNA AND LUPUS NEPHRITIS [J].
FOURNIE, GJ .
KIDNEY INTERNATIONAL, 1988, 33 (02) :487-497
[10]  
GOES N, 1995, TRANSPLANTATION, V59, P565